Sweden: Karo Pharma announces terms of rights issue to take out bridge

Sweden-based Karo Pharma, which owns and commercialises branded, original over-the-counter products and prescription medicines, is to issue of approximately Skr2.508bn (US$270m) in new shares via a rights issue at a subscription price of Skr52 per each share. Shareholders have preferential rights to subscribe for three new shares per 14 existing shares. Karo Pharma’s largest shareholder,…

You must be a HMI Subscriber to view this content.

Subscribe Now »